LeMaitre Vascular, Inc.

Equities

LMAT

US5255582018

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
62.99 ^USD	-1.62%		+0.59%	+10.98%

Mar. 12	Lemaitre Vascular Insider Sold Shares Worth $309,684, According to a Recent SEC Filing	MT
Mar. 07	Lemaitre Vascular Insider Sold Shares Worth $344,925, According to a Recent SEC Filing	MT

LeMaitre to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 01, 2022 at 04:26 pm EDT

BURLINGTON, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the Canaccord Genuity 42^nd Annual Growth Conference on Thursday, August 11, 2022, at 12:00 PM ET at the InterContinental Hotel, Boston.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

Contact:

Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
smillar@lemaitre.com

Primary Logo

Source: LeMaitre Vascular, Inc.

2022 GlobeNewswire, Inc., source Press Releases

Latest news about LeMaitre Vascular, Inc.

Lemaitre Vascular Insider Sold Shares Worth $309,684, According to a Recent SEC Filing	Mar. 12	MT
Lemaitre Vascular Insider Sold Shares Worth $344,925, According to a Recent SEC Filing	Mar. 07	MT
Lemaitre Vascular Insider Sold Shares Worth $517,500, According to a Recent SEC Filing	Mar. 07	MT
Health Care Drops After Mixed Earnings -- Health Care Roundup	Feb. 28	DJ
Barrington Raises Price Target on LeMaitre Vascular to $69 From $66, Keeps Outperform Rating	Feb. 28	MT
LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on March 28, 2024	Feb. 27	CI
LeMaitre Vascular, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Feb. 27	CI
LeMaitre Vascular, Inc. announces an Equity Buyback for $50 million worth of its shares.	Feb. 27	CI
LeMaitre Vascular, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Transcript : LeMaitre Vascular, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
(LMAT) LEMAITRE VASCULAR Forecasts Fiscal Year 2024 EPS $1.65	Feb. 27	MT
(LMAT) LEMAITRE VASCULAR Expects Q1 EPS $0.28	Feb. 27	MT
Earnings Flash (LMAT) LEMAITRE VASCULAR Reports Q4 Revenue $48.9M, vs. Street Est of $49M	Feb. 27	MT
LeMaitre Vascular, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
LeMaitre Vascular, Inc. authorizes a Buyback Plan.	Feb. 20	CI
Tranche Update on LeMaitre Vascular, Inc.'s Equity Buyback Plan announced on February 23, 2023.	Nov. 07	CI
Transcript : LeMaitre Vascular, Inc., Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01
Earnings Flash (LMAT) LEMAITRE VASCULAR Posts Q3 Revenue $47.4M, vs. Street Est of $47.6M	Nov. 01	MT
LeMaitre Vascular, Inc. Approves Quarterly Dividend, Payable on November 30, 2023	Nov. 01	CI
LeMaitre Vascular, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
JMP Securities Initiates LeMaitre Vascular With Market Outperform Rating, Price Target is $60	23-10-23	MT
Oppenheimer Initiates Coverage on LeMaitre Vascular With Outperform Rating, $70 Price Target	23-09-06	MT
Tranche Update on LeMaitre Vascular, Inc.'s Equity Buyback Plan announced on February 23, 2023.	23-08-08	CI
North American Morning Briefing : Stocks Seen -2-	23-08-04	DJ
Jefferies Downgrades LeMaitre Vascular to Hold From Buy, Adjusts Price Target to $67 From $63	23-08-03	MT

Chart LeMaitre Vascular, Inc.

Duration

Period

More charts

Company Profile

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for LeMaitre Vascular, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

62.99 USD

Average target price

71.29 USD

Spread / Average Target

+13.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
LEMAITRE VASCULAR, INC.	+10.98%	1.44B
THERMO FISHER SCIENTIFIC	+7.71%	220B
DANAHER CORPORATION	+6.25%	185B
INTUITIVE SURGICAL, INC.	+10.60%	133B
BOSTON SCIENTIFIC CORPORATION	+26.73%	107B
SIEMENS HEALTHINEERS AG	-0.57%	62.91B
EDWARDS LIFESCIENCES CORPORATION	+15.42%	53.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.71B
AGILENT TECHNOLOGIES, INC.	-1.91%	40.29B
GE HEALTHCARE TECHNOLOGIES INC.	+11.16%	39.57B

Other Advanced Medical Equipment & Technology